Alnylam Pharmaceuticals gains FDA approval for Amvuttra in ATTR-CM, boosting revenue prospects. Click here to read an ...

The approval expands the indication for Amvuttra, which now becomes the first and only therapeutic approved by the FDA for ...

Cantor Fitzgerald said that while the firm “congratulates” Alnylam Pharmaceuticals (ALNY) on last week’s Amvuttra approval, with the stock ...

Initially, Amvuttra’s annual list price will be nearly double the yearly cost of rival medicines from Pfizer and BridgeBio. But executives argue its “compelling and highly differentiated value” ...

CM, expanding its market reach. JP Morgan upgrades the stock, projecting strong sales and a multi-billion opportunity.

Alnylam Pharmaceuticals’ Amvuttra (vutrisiran) has been approved by the Food and Drug Administration (FDA) to treat ...

Amvuttra is now approved in the US to treat both cardiomyopathy and polyneuropathy manifestations of ATTR amyloidosis.

Alnylam has the FDA approval it sought for Amvuttra in a form of cardiomyopathy associated with rare disease ATTR amyloidosis ...

The FDA has approved a new drug for a serious heart condition that affects thousands of people. The drug, called Amvuttra ...

The U.S. Food and Drug Administration has approved Alnylam Pharmaceuticals drug Amvuttra to treat transthyretin amyloid ...

Alnylam Pharmaceuticals ALNY announced that the FDA had approved its regulatory filing seeking the label expansion of its lead drug, Amvuttra (vutrisiran), for treating the cardiomyopathy of wild ...

ATTR-CM is a disease in which harmful proteins build up in the heart, making it harder to pump blood, according to the ...